Efgartigimod and Methylprednisolone for Neuromyelitis Optica
Author Information
Author(s): Yang Wenjing, Chen Pei, Guo Jiaxuan, Feng Huiyu, Huang Xin
Primary Institution: The First Affiliated Hospital, Sun Yat-Sen University
Hypothesis
The study evaluates the efficacy of efgartigimod combined with intravenous methylprednisolone in treating acute neuromyelitis optica spectrum disorders.
Conclusion
Efgartigimod combined with IVMP is safe and well-tolerated, showing better efficacy in reducing disability scores compared to IVMP alone.
Supporting Evidence
- Efgartigimod plus IVMP reduced EDSS scores by 0.5 compared to 0.27 in the IVMP group.
- 50% of patients in the efgartigimod group showed improvement in EDSS scores.
- No serious adverse events were reported in either treatment group.
Takeaway
This study shows that a new treatment combining two medicines can help people with a serious nerve disease feel better and have fewer problems.
Methodology
The study reviewed medical records of NMOSD patients treated with efgartigimod plus IVMP or IVMP alone, assessing treatment efficacy through EDSS scores before and after treatment.
Limitations
The study's retrospective design and small sample size limit the generalizability of the findings.
Participant Demographics
All participants were female, aged between 30 and 70 years.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website